Recombinant Human PD-L2/B7-DC His-tag Protein, CF

Catalog #: 9075-PL Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
9075-PL-100
9075-PL-01M

Recombinant Human PD-L2/B7-DC His-tag Protein Binding Activity

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human PD-L2/B7-DC His-tag Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human PD‑L2/B7‑DC is immobilized at 1 µg/mL (100 µL/well), the concentration of Recombinant Human PD‑1 Fc Chimera (Catalog # 1086-PD) that produces 50% of the optimal binding response is 0.08-0.4 μg/mL.

Source

Human embryonic kidney cell, HEK293-derived human PD-L2/B7-DC protein
Leu20-Pro219, with a C-terminal 6-His tag

Accession #

Q9BQ51

N-terminal Sequence
Analysis

Leu20

Predicted Molecular Mass

23 kDa

SDS-PAGE

29-47 kDa, reducing conditions

Product Datasheets

9075-PL

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

9075-PL

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

When Recombinant Human PD-L2/B7-DC is immobilized at 1 µg/mL, Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD) binds with an ED₅₀ of 0.08-0.4 µg/mL.

Reconstitution Calculator

Background: PD-L2/B7-DC

Programmed Death Ligand 2 (PD-L2), also known as B7-DC and butyrophilin-like protein, is a member of the B7 family of proteins that provide signals for regulating T-cell activation and tolerance (1). Mature human PD-L2 consists of a 201 amino acid (aa) extracellular domain (ECD) with one V-like and one C-like Ig domain, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain (2, 3). Within the ECD, mouse and human PD-L2 share 72% aa sequence identity. Alternative splicing generates additional isoforms that lack the second Ig-like domain and may be substituted and truncated following the first Ig-like domain (4). PD-L2 is expressed on dendritic cells, subsets of activated CD4⁺ and CD8⁺ T cells, and memory B cells that differentiate into plasma cells (3, 5, 6). At inflammatory sites such as rheumatoid arthritis, allergen exposure, and virus infection, PD-L2 is up-regulated on synoviocytes, infiltrating macrophages, dendritic cells, and airway epithelial cells (7-11). PD-L2, along with B7-H1/PD-L1, binds to T cell PD-1 where it promotes IFN-gamma production and CD40 Ligand up-regulation while inhibiting IL-4 production (2, 3, 12, 13). In addition, PD-L2 binds to RGM-B on macrophages and alveolar epithelial cells, supporting respiratory immune tolerance (14). In asthma, PD-L2 suppresses IL-5 and IL-13 production, promotes IL-12 production by dendritic cells, and supports allergen-induced airway hyper-responsiveness and mucus production (9, 11).

References

Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
Latchman, Y. et al. (2001) Nat. Immunol. 2:261.
Tseng, S.-Y. et al. (2001) J. Exp. Med. 193:839.
He, X.-H. et al. (2004) Acta Biochim. Biophys. Sinica 36:284.
Messal, N. et al. (2011) Mol. Immunol. 48:2214.
Zuccarino-Catania, G.V. et al. (2014) Nat. Immunol. 15:631.
Guo, G. et al. (2012) Clin. Rheumatol. 31:271.
Loke, P. and J.P. Allison (2003) Proc. Natl. Acad. Sci. USA 100:5336.
Matsumoto, K. et al. (2004) J. Immunol. 172:2530.
Stanciu, L.A. et al. (2006) J. Infec. Dis. 193:404.
Lewkowich, I.P. et al. (2013) Mucosal Immun. 6:728.
Ghiotto, M. et al. (2010) Int. Immunol. 22:651.
Shin, T. et al. (2003) J. Exp. Med. 198:31.
Xiao, Y. et al. (2014) J. Exp. Med. 211:943.

Long Name

Programmed Death-1 Ligand-2

Entrez Gene IDs

80380 (Human); 58205 (Mouse); 309304 (Rat); 102146227 (Cynomolgus Monkey)

Alternate Names

B7-DC; bA574F11.2; Btdc; Butyrophilin B7-DC; Butyrophilin-like Protein; CD273 antigen; CD273; CD273PD-1 ligand 2; MGC142240; PD-1-ligand 2; PDCD1L2MGC142238; PDCD1LG2; PDL2; PD-L2; PDL2B7DC; PD-L2PDCD1 ligand 2; programmed cell death 1 ligand 2; Programmed death ligand 2